Windtree Therapeutics Business Overview and Updates

Author

Reads 6.6K

Medical Practitioners doing a research on a Lab
Credit: pexels.com, Medical Practitioners doing a research on a Lab

Windtree Therapeutics is a biopharmaceutical company focused on developing innovative treatments for respiratory and dermatological diseases. Founded in 2010, the company has been working tirelessly to bring new therapies to market.

The company's pipeline includes a range of products, including a novel inhaled bronchodilator for chronic obstructive pulmonary disease (COPD) and asthma. This treatment has the potential to provide significant relief for patients suffering from these debilitating conditions.

Windtree Therapeutics has made significant progress in recent years, with several key milestones achieved in the development of its pipeline products.

Istaroxime Updates

Istaroxime is a promising drug candidate for treating acute heart failure and cardiogenic shock. Windtree Therapeutics has secured a new U.S. patent for istaroxime, covering its intravenous formulation and extending protection until 2039.

The patent is particularly significant as it covers a critical treatment area, with acute heart failure affecting 1.3 million hospitalized patients annually in the U.S. and representing the leading cause of hospitalization for patients over 65 years old.

Credit: youtube.com, Unveiling The Potential Of Istaroxime W/ Windtree Therapeutics' SEISMiC Extension Study

Windtree Therapeutics has also announced positive interim analysis results from its SEISMiC C Phase 2 study evaluating istaroxime in SCAI Stage C cardiogenic shock patients. The study demonstrated that istaroxime maintained its safety profile and showed consistent physiological improvements when combined with current standard treatments.

The company plans to advance to a global Phase 3 trial based on these encouraging results, which will be crucial for Phase 3 readiness and upcoming FDA discussions.

Company News

Windtree Therapeutics is a biopharmaceutical company with a focus on developing innovative treatments for respiratory diseases.

The company was founded in 2013 and is headquartered in State College, Pennsylvania.

Windtree's pipeline includes a novel, non-invasive aerosol delivery technology that has shown promise in treating respiratory conditions such as cystic fibrosis.

Receives Nasdaq Non-Compliance Notice

The company received a Nasdaq Non-Compliance Notice due to low stock prices.

The notice was issued on January 2nd, and the company has 180 days to regain compliance by meeting the minimum stock price requirement of $1 per share.

Credit: youtube.com, How to Spot Nasdaq Delisting Risk (The Investor's Guide)

The company's stock price has been struggling to stay above $1 per share, and this notice is a warning that they need to take action to prevent delisting.

The company has a history of volatility, with significant fluctuations in stock price over the years, which has contributed to their current non-compliance status.

They must take concrete steps to address the issue and ensure their stock price meets the necessary requirements to avoid delisting.

Evofem to Cut PheXXi Manufacturing Costs

Evofem is working to cut PheXXi manufacturing costs. Windtree Therapeutics has inked a sourcing agreement to help make this happen.

The agreement aims to reduce PheXXi manufacturing costs by over 50% by the end of 2025. This is a significant step towards making the hormone-free, on-demand prescription contraceptive gel more affordable.

Windtree is rapidly advancing lower cost PheXXi manufacturing under this agreement. This will likely have a positive impact on Evofem's bottom line.

Evofem has already seen a reduction in operating expenses, with a 27% decrease from 2023 levels.

Financials

Credit: youtube.com, My Take on Windtree Therapeutics' Debt Strategy & Risks

Windtree Therapeutics is a biotechnology company based in WARRINGTON, Pa. Their headquarters is located in this city.

The company is listed on the NasdaqCM under the ticker symbol WINT. This is the stock exchange where investors can buy and sell shares of Windtree Therapeutics.

In December 2024, Windtree Therapeutics announced their financial performance, which is an important aspect of any company's growth.

Their stockholders have approved key proposals for revenue and profit generation, which is a positive sign for the company's future.

Biotech and Research

Windtree Therapeutics has received $1.6 million in funding. This funding was announced on October 8th.

Windtree Therapeutics also made headlines with the resignation of Steven G. Simonson as Senior Vice President and Chief Medical Officer, which took effect on September 2, 2025.

As of the latest data, Windtree Therapeutics' stock price has experienced a significant fluctuation, with a 16.98% increase in the past 5 days.

Phase 2 Interim Analysis in Cardiogenic Shock Patients

Credit: youtube.com, Cardiogenic Shock in 2021: A.S.W.O.T. Analysis

Windtree Therapeutics has announced positive interim analysis results from its SEISMiC C Phase 2 study evaluating istaroxime in SCAI Stage C cardiogenic shock patients. The study demonstrated that istaroxime maintained its safety profile and showed consistent physiological improvements when combined with current standard treatments.

The global, placebo-controlled, double-blinded trial included sites across the U.S., Europe, and Latin America, building upon previous successful SEISMIC B study results. The interim analysis of the first 20 patients revealed no new safety concerns or excess arrhythmias when istaroxime was administered alongside standard therapies.

The company plans to advance to a global Phase 3 trial based on these encouraging results. This is a significant step forward for Windtree and its potential treatment for cardiogenic shock patients.

The SEISMiC C trial is a crucial part of Windtree's istaroxime cardiogenic shock development program, following two previously successful Phase 2 studies in SCAI Stage B patients.

A different take: Paramount Global

Biotechnology & Medical Research

Windtree Therapeutics, Inc. received $1.6 million in funding on October 8th. This is a significant amount for any biotech company.

Credit: youtube.com, Pursuing a Career in Scientific Research | Allen Chan | TEDxYouth@DBSHK

The company has a market capitalization of $3.45 million, which is a relatively small amount compared to other companies in the industry. For example, Lonza Group AG has a market capitalization of $49.45 billion.

Windtree Therapeutics, Inc. announced the resignation of Steven G. Simonson as Senior Vice President and Chief Medical Officer on September 2, 2025. This change in leadership may have an impact on the company's future.

Here's a list of some key statistics for Windtree Therapeutics, Inc. compared to other companies in the industry:

These statistics give us a glimpse into the performance of Windtree Therapeutics, Inc. compared to other companies in the industry.

Lower Cost Hormone-Free Contraceptive Gel

Windtree Therapeutics is rapidly advancing the lower cost manufacturing of PHEXXI, a hormone-free, on-demand prescription contraceptive gel. PHEXXI is a game-changer for women seeking reliable and convenient birth control.

By partnering with an outside U.S. manufacturer, Windtree aims to cut PHEXXI manufacturing costs by over 50% by the end of 2025. This significant reduction in costs will make PHEXXI more accessible to women who need it.

The cost savings will be achieved through a contract inked in March 2025, which marks a significant milestone in Windtree's efforts to make PHEXXI more affordable.

Stock Performance

Credit: youtube.com, Windtree Therapeutics The Unexpected Stock High Flyer - The Sky’s The Limit?

Windtree Therapeutics has seen its share price fluctuate significantly over the past year. The current share price is US$0.12, which is a far cry from the 52-week high of US$45.50.

The company's stock has experienced a 49.88% increase in the last month, but this is a stark contrast to the 87.77% decline over the past three months. The 1-year change is a staggering -99.71%.

Here are some key statistics that give you a sense of the company's performance:

In comparison to other companies in the biotechnology industry, Windtree Therapeutics has underperformed. Over the past year, the US Biotechs industry returned 2.6%, while Windtree Therapeutics saw a -99.7% decline.

About the Company

Windtree Therapeutics is a biotechnology company that focuses on developing therapeutics for acute cardiovascular diseases.

The company's lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure and early cardiogenic shock.

Credit: youtube.com, Windtree Therapeutics (NASDAQ: $WINT): What Is SERCA2a And Why Is It Important?

Windtree also develops AEROSURF, an aerosolized KL4 surfactant for treating respiratory distress syndrome in premature infants, and Surfaxin, a lyophilized KL4 surfactant for treating respiratory diseases in humans.

Istaroxime is being tested for its potential to treat two serious conditions: acute decompensated heart failure and early cardiogenic shock.

AEROSURF and Surfaxin are both in Phase 2b clinical trials, which is a significant stage in the development of new treatments.

Windtree's product pipeline also includes Rostafuroxin, which is in Phase 2b clinical trials for treating genetically associated hypertension.

The company is working on oral and intravenous SERCA2a activators, which are in preclinical trials for the treatment of chronic and acute heart failure.

Frequently Asked Questions

Is Wint a good stock to buy?

Windtree Therapeutics, Inc. stock's performance is uncertain, with a Momentum Grade of F, suggesting it may not be the best choice for growth or momentum investors. Consider your individual goals and risk tolerance before making a decision.

What happened to Windtree Therapeutics?

Windtree Therapeutics' stock plummeted 77.21% on August 20, leading to a loss of its Nasdaq listing due to noncompliance with listing rules. The company's stock price dropped to $0.0942 after hours.

Who is the CEO of Windtree Therapeutics?

Jed Latkin is the CEO of Windtree Therapeutics. He previously served as the company's Chief Financial Officer.

Carolyn VonRueden

Junior Writer

Carolyn VonRueden is a versatile writer with a passion for crafting engaging content on a wide range of topics. With a keen eye for detail and a knack for research, Carolyn has established herself as a reliable voice in the world of finance and travel writing. Her portfolio boasts a diverse array of article categories, from exploring the benefits of cash cards to delving into the intricacies of Delta SkyMiles payment options.

Love What You Read? Stay Updated!

Join our community for insights, tips, and more.